Page last updated: 2024-10-28

hexamethonium and Ventricular Fibrillation

hexamethonium has been researched along with Ventricular Fibrillation in 1 studies

Hexamethonium: A nicotinic cholinergic antagonist often referred to as the prototypical ganglionic blocker. It is poorly absorbed from the gastrointestinal tract and does not cross the blood-brain barrier. It has been used for a variety of therapeutic purposes including hypertension but, like the other ganglionic blockers, it has been replaced by more specific drugs for most purposes, although it is widely used a research tool.

Ventricular Fibrillation: A potentially lethal cardiac arrhythmia that is characterized by uncoordinated extremely rapid firing of electrical impulses (400-600/min) in HEART VENTRICLES. Such asynchronous ventricular quivering or fibrillation prevents any effective cardiac output and results in unconsciousness (SYNCOPE). It is one of the major electrocardiographic patterns seen with CARDIAC ARREST.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19901 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Ohyanagi, M1
Matsumori, Y1
Iwasaki, T1

Other Studies

1 other study available for hexamethonium and Ventricular Fibrillation

ArticleYear
Beta-adrenergic receptors in ischemic and nonischemic canine myocardium: relation to ventricular fibrillation and effects of pretreatment with propranolol and hexamethonium.
    Journal of cardiovascular pharmacology, 1988, Volume: 11, Issue:1

    Topics: Animals; Coronary Disease; Coronary Vessels; Cyclic AMP; Dogs; Heart; Hexamethonium; Hexamethonium C

1988